62. 発作性夜間ヘモグロビン尿症 Paroxysmal nocturnal hemoglobinuria Clinical trials / Disease details


臨床試験数 : 292 薬物数 : 151 - (DrugBank : 49) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 108

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01194804
(ClinicalTrials.gov)
April 200830/8/2010E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria PatientsPhase II Clinical Study of Eculizumab (h5G1.1-mAb) in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Extension Study to C07-001 ProtocolParoxysmal Nocturnal HemoglobinuriaDrug: EculizumabAlexion PharmaceuticalsCMIC Co, Ltd. JapanCompleted12 YearsN/AAll27Phase 2NULL
2NCT01192399
(ClinicalTrials.gov)
November 200730/8/2010Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria PatientsPhase II Clinical Study of Eculizumab (h5G1.1-mAb) in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) PatientsParoxysmal Nocturnal HemoglobinuriaBiological: EculizumabAlexion PharmaceuticalsNULLCompleted12 YearsN/AAll29Phase 2NULL
3EUCTR2005-000043-28-IT
(EUCTR)
01/09/200506/02/2007A Phase III Open label extension study of Eculizumab in patients with transfusion dependent hemolytic paroxysmal nocturnal hemoglobinuria PNH who have participated in Triumph C04-001 , Shepherd C04-002 or X03-001 studiesA Phase III Open label extension study of Eculizumab in patients with transfusion dependent hemolytic paroxysmal nocturnal hemoglobinuria PNH who have participated in Triumph C04-001 , Shepherd C04-002 or X03-001 studies paroxymal nocturnal hemoglobinuria
MedDRA version: 6.1;Level: PT;Classification code 10034042
Product Name: Eculizumab
Product Code: h5G1.1-mAb
Product Name: Eculizumab
Product Code: h5G1.1-mAb
ALEXION PHARMACEUTICALS INCNULLNot RecruitingFemale: yes
Male: yes
170Phase 3Germany;United Kingdom;Spain;Ireland;Italy;Sweden